PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases

Cancer Investigation

Volumn 29, Issue 7, 2011, Pages 427-438

  Hager, Martina ^a   Haufe, Heike ^a   Lusuardi, Lukas ^a   Schmeller, Nikolaus ^b   Kolbitsch, Christian ^c  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Metastases; PAKT; PmTOR; Primary renal cell carcinoma; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CELLULAR DISTRIBUTION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE METASTASIS; MALE; MEMORIAL SLOAN KETTERING CANCER CENTER SCORE; METASTASIS; PAPILLARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY;

AGED; CARCINOMA, RENAL CELL; CYTOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES;

EID: 79960162068     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.584782     Document Type: Article

References (54)

1. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
2. Downward J. PI 3-kinase, Akt, and cell survival. Semin Cell Dev Biol 2004;15:177-182.
3. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96:4240-4245. (Pubitemid 29190320)
4. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
5. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003;28:573-576.
6. Morgensztern D, Mc Leod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005;16:797-803. (Pubitemid 41215743)
7. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, Ellis IO. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004;204:93-100. (Pubitemid 39214486)
8. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-6871. (Pubitemid 39383035)
9. Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 2009;13:2181-2188.
10. Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 2003;169:710-713. (Pubitemid 36133028)
11. Hsu J, ShiY,Krajewski S, Renner S, FisherM, Reed JC, Franke TF, Lichtenstein A. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98:2853-2855.
12. Kreisberg JI,Malik SN, Prihoda TJ, Bedolla RG, TroyerDA, Kreisberg S, Ghosh PM. Phosphorylation ofAkt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-5236. (Pubitemid 39006542)
13. Massarelli E, Liu DD, Lee JJ, El Naggar AK, Lo ML, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005;104:2430-2436. (Pubitemid 41691564)
14. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-6111. (Pubitemid 32762546)
15. Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, Rutqvist LE. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003;5:R37-R44.
16. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 2006;12:3070-3077. (Pubitemid 43837353)
17. Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005;14:389-392.
18. Yamamoto S, Tomita Y, Hoshida Y,Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:2846-2850. (Pubitemid 38509164)
19. Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther 2005;5:1031-1040. (Pubitemid 43033793)
20. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005;16:928-933. (Pubitemid 40903919)
21. Park JY, Lin PY, Weiss RH. Targeting the PI3K-Akt pathway in kidney cancer. Expert Rev Anticancer Ther 2007;7:863-870. (Pubitemid 47007992)
22. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379-385. (Pubitemid 47584475)
23. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-2267. (Pubitemid 46801555)
24. Lee JS, Kim HS, Kim YB, Lee MC, Park CS. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 2003;84:166-172. (Pubitemid 37363160)
25. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-663. (Pubitemid 13234762)
26. Wittekind C, Meyer HJ, Bootz F. UICC TNMKlassifikationMaligner Tumoren. Berlin, Germany: Springer, 2002, pp 181-183.
27. Eble JN, Sauter G, Epstein JI, Sesterhenn A. WHO Classification of Tumours. Tumors of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004, pp 23-34.
28. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540. (Pubitemid 29368255)
29. Craven RJ, Lightfoot H, CanceWG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol 2003;12:39-49.
30. Facchinetti V, OuyangW,Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC,Mao Y, Miao RQ, Sessa WC,Qin J, Zhang P, Su B, Jacinto E.The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008;27:1932-1943.
31. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395. (Pubitemid 34214843)
32. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101. (Pubitemid 40262113)
33. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004;15:1510-1516. (Pubitemid 39409742)
34. Xu G, ZhangW, Bertram P, Zheng XF,Mc Leod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004;24:893-900.
35. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J,McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
36. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an over expressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 2006;36:283-293. (Pubitemid 44320422)
37. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG,Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002;99:53-57. (Pubitemid 34273197)
38. Hager M, Haufe H, Kemmerling R, Mikuz G, Kolbitsch C, Moser PL. PTENexpression in renal cell carcinoma and oncocytoma and prognosis. Pathology 2007;39:482-485. (Pubitemid 47450589)
39. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 2000;156:1693-1700. (Pubitemid 30646707)
40. Martelli AM, Cocco L, Capitani S, Miscia S, Papa S, Manzoli FA. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis. Eur J Histochem 2007;51(Suppl 1):125-131.
41. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C.Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000;157:1097-1103.
42. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, MiyakawaM, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2004;41:161-170.
43. Whiteman DC, Zhou XP, CummingsMC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002;99:63-67. (Pubitemid 34273199)
44. Youssif TA, Fahmy MA, Koumakpayi IH, Ayala F, Al Marzooqi S, Chen G, Tamboli P, Squire J, Tanguay S, Sircar K. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011;117:290-300.
45. Chung JH,Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005;65:4108-4116. (Pubitemid 40775648)
46. Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C.The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. HumMol Genet 2006;15:2553-2559. (Pubitemid 44288685)
47. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-7464. (Pubitemid 41637985)
48. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3- kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 2003;31:573-578. (Pubitemid 36750733)
49. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-2106. (Pubitemid 32545195)
50. Van de ST, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, Swinnen JV. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 2005;206:214-219. (Pubitemid 40754025)
51. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-352. (Pubitemid 44879483)
52. He L, Fan C, Gillis A, Feng X, Sanatani M, Hotte S, Kapoor A, Tang D. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim Biophys Acta 2007;1772:1134-1142. (Pubitemid 350184271)
53. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000;157:1123-1128.
54. Baker AF, Dragovich T, Ihle NT,Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005;11:4338-4340. (Pubitemid 40825621)